Currently antibodies targeting cytotoxic T lymphocyte associated protein 4 (CTLA4) and the programmed cell death protein 1 and its ligand (PD-1, PD-L1) are utilised clinically, and T cell modulators are indicated for treatment of c.50 cancer types [5]. Here, PDCD1 is linked to cancer.